GGrantIndex
← Leaderboards

Nancy F Olivieri

Hospital For Sick Chldrn (Toronto)

$2,063,229
Attributed
$2,063,229
Total exposure
4
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $370.9K · FY200509
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09

Funding mix

By agency

NIH$4,327,134 · 5

By mechanism

U01$3,179,910 · 3
R01$1,147,224 · 2

Top collaborators

No co-investigators on record.

Others in their field

Top investigators on “Thalassemia

Research focus

ThalassemiaHuman Therapy EvaluationBlood Disorder ChemotherapyClinical ResearchHuman SubjectTransferrinErythropoiesisDrug Administration Rate /DurationCanadaDeferoxaminePeroxidationChelating AgentsHemoglobin FIronClinical TrialsStimulant /AgonistGenetically Modified AnimalsLaboratory MouseSubcutaneousEuropeFetal HemoglobinCompliance BehaviorBlood DrugGene Expression

Grant awards (27)

Thalassemia Clinical Research Network, Canada$185,469
U01 · FY2009 · HL · contact PI
AUGMENTATION OF FETAL HEMOGLOBIN IN THALASSEMIA$92,735
U01 · FY2009 · HL · contact PI
PROSPECTIVE COMPARISON OF TWO REGIMENS OF DEFEROXAMINE$92,734
U01 · FY2009 · HL · contact PI
Thalassemia Clinical Research Network, Canada$181,491
U01 · FY2008 · HL · contact PI
AUGMENTATION OF FETAL HEMOGLOBIN IN THALASSEMIA$90,746
U01 · FY2008 · HL · contact PI
PROSPECTIVE COMPARISON OF TWO REGIMENS OF DEFEROXAMINE$90,745
U01 · FY2008 · HL · contact PI
Thalassemia Clinical Research Network, Canada$177,625
U01 · FY2007 · HL · contact PI
AUGMENTATION OF FETAL HEMOGLOBIN IN THALASSEMIA$88,813
U01 · FY2007 · HL · contact PI
PROSPECTIVE COMPARISON OF TWO REGIMENS OF DEFEROXAMINE$88,812
U01 · FY2007 · HL · contact PI
Thalassemia Clinical Research Network, Canada$179,064
U01 · FY2006 · HL · contact PI
AUGMENTATION OF FETAL HEMOGLOBIN IN THALASSEMIA$1
U01 · FY2006 · HL · contact PI
PROSPECTIVE COMPARISON OF TWO REGIMENS OF DEFEROXAMINE$1
U01 · FY2006 · HL · contact PI
Thalassemia Clinical Research Network, Canada$178,200
U01 · FY2005 · HL
PROSPECTIVE COMPARISON OF TWO REGIMENS OF DEFEROXAMINE$371,418
U01 · FY2004 · HL
STUDY OF THALASSEMIA AND TREATMENT$321,359
U01 · FY2004 · HL
STUDY OF THALASSEMIA AND TREATMENT$360,600
U01 · FY2003 · HL
AUGMENTATION OF FETAL HEMOGLOBIN IN BETA THALASSEMIA$198,677
R01 · FY2003 · HL
STUDY OF THALASSEMIA AND TREATMENT$350,097
U01 · FY2002 · HL
AUGMENTATION OF FETAL HEMOGLOBIN IN BETA THALASSEMIA$200,022
R01 · FY2002 · HL
AUGMENTATION OF FETAL HEMOGLOBIN IN THALASSEMIA$0
U01 · FY2002 · HL
PROSPECTIVE COMPARISON OF TWO REGIMENS OF DEFEROXAMINE$0
U01 · FY2002 · HL
AUGMENTATION OF FETAL HEMOGLOBIN IN BETA THALASSEMIA$212,222
R01 · FY2001 · HL
DEFERIPRONE THERAPY FOR SICKLE CELL DISEASE$87,775
R01 · FY2001 · HL
DEFERIPRONE THERAPY FOR SICKLE CELL DISEASE$77,892
R01 · FY2001 · HL
STUDY OF THALASSEMIA AND TREATMENT$330,000
U01 · FY2000 · HL
AUGMENTATION OF FETAL HEMOGLOBIN IN BETA THALASSEMIA$205,626
R01 · FY2000 · HL
DEFERIPRONE THERAPY FOR SICKLE CELL DISEASE$165,010
R01 · FY2000 · HL